Investigator-Initiated Trials
As part of our commitment to delivering innovative therapies to patients worldwide, Novartis believes in the need to support ethical independent clinical research conducted by qualified third-party investigators.
The value of the scientific research produced by such investigators is key to complementing Novartis-sponsored research in helping to ensure we better understand the benefit/risk profile of our therapies, as well as to explore new opportunities to address unmet medical needs.
Such clinical research must set out to address meaningful scientific and/or clinical objectives supported by valid study designs in which the privacy rights, safety and welfare of patients is of paramount importance.
Novartis defines IITs as “studies with scientific and medical merit developed and sponsored by an independent investigator or academic sponsor. An IIT may be a clinical or non-clinical study conducted without the participation of Novartis, for which the IIT sponsor requests Novartis to provide either funding, drug product or both.”
For IIT related questions, please contact the medical team in your Novartis local country office.
Novartis global investigator-initiated trial guidelines (PDF 0.3 MB)